



AGENDA

POETIC Summer Meeting

July 26th – 27th, 2018

Banff Centre for Arts & Creativity

Banff, Alberta Canada

WEDNESDAY, JULY 25

EVENING SESSION

4:00 PM MT (6:00 PM EST) | Banff Centre for Arts & Creativity | Room KC204

4:00 PM MT (6:00 EST) **BOARD OF DIRECTORS MEETING** (Closed Meeting)

5:00 PM **DINNER**
Board of Directors

THURSDAY, JULY 26

MORNING SESSION

7:30 AM – 1:15 PM | Banff Centre for Arts & Creativity | Room KC203

7:30 – 8:15 AM **REGISTRATION/BREAKFAST**
Vistas Dining Room

GREETINGS/INTRODUCTIONS

Aru Narendran, MD, PhD, Alberta Children's Hospital

Victor Lewis, MD, Division Head, Hematology/Oncology and Bone Marrow Transplantation, Alberta Children's Hospital

WELCOME ADDRESS

8:15 – 8:30 AM *Tanya Trippett, MD, Memorial Sloan Kettering Cancer Center
Co-Founder and Director, POETIC*

8:30 – 9:30 AM

KEYNOTE ADDRESS

8:30 – 9:00 AM

Immune Modulation by the Extracellular Matrix

*Pinaki Bose, PhD, Director, Tumour Biology and Translational Research
University of Calgary*

9:00 – 9:30 AM

Tackling Intra-Tumor Heterogeneity for Precision Medicine: Challenges and Opportunities

Sorana Morrissy, PhD, Assistant Professor, Department of Biochemistry & Molecular Biology, Cumming School of Medicine, University of Calgary

9:30 – 9:35 AM

BREAK

9:35 AM – 12:35 PM

THERAPEUTIC STRATEGIES FOR TARGETED DELIVERY

9:35 – 10:35 AM

Preclinical Development of miR loaded Exosomal Vesicles

*Stephen Gould, PhD, Professor Biologic Chemistry, Johns Hopkins University
David Lyden, MD, PhD, Weill Cornell Medical Center*

10:35 – 11:35 AM

Downstream Analysis of miR loaded Exosomal Vesicles

*Olga Kovalchuk, MD, PhD, University of Lethbridge
Bodour Salhia, PhD, University of Southern California
Michael Roehrl, MD, PhD, Memorial Sloan Kettering Cancer Center**

**Will be attending via conference call.*

11:35 AM – 12:05 PM

Preclinical & Clinical Development of Taurolidine NanoPro™

Tony Pfaffle, MD, Chief Scientific Officer, Cormedix, Inc.

12:05 – 12:35 PM

POETIC International Initiative

*Tanya Trippett, MD, Memorial Sloan Kettering Cancer Center
David Lyden, MD, PhD, Weill Cornell Medical Center
Bodour Salhia, PhD, University of Southern California*

12:35 – 1:15 PM

LUNCH

Vistas Dining Room

AFTERNOON SESSION

1:15 – 5:00 PM | Banff Centre for Arts & Creativity | Room KC203

1:15 – 3:15 PM

THERAPEUTIC STRATEGIES EXPLORING IMMUNOTHERAPEUTIC APPROACHES

Preclinical Development of PV-10

*Eric Wachter, PhD, Chief Technology Officer and Director
Provectus Biopharmaceuticals, Inc.*

Aru Narendran, MD, PhD, Alberta Children's Hospital

Clinical Development of PV-10

*Eric Wachter, PhD, Chief Technology Officer and Director
Provectus Biopharmaceuticals, Inc.*

1:15 – 2:15 PM

*Tanya Trippett, MD, Memorial Sloan Kettering Cancer Center
Todd Heaton, MD, Memorial Sloan Kettering Cancer Center*

Myeloid-lineage p53 As a Novel Target for Immunotherapy

David Munn, MD, Pediatric Immunotherapy Program

Medical College of Georgia

2:15 – 3:15 PM

3:15 – 3:30 PM

BREAK

iMATRIX Trials: Clinical update

Stephen Simko, MD, Medical Director

Innovative Pediatric Oncology Drug Development, Genentech

3:30 – 4:30 PM

CLINICAL TRIALS UNDER DEVELOPMENT

Selinexor/Cabazitaxel Concept

Norman Lacayo, MD, Lucile Packard Children's Hospital

4:30 – 5:00 PM

PHARMACY UPDATE

Morad Balas, Clinical Coordinator for Pharmacy Services

Memorial Sloan Kettering Cancer Center

5:00 – 5:15 PM

5:15 PM

MEETING ADJOURN

DINNER

Banff Centre for Arts & Creativity | Room KC201

6:00 PM

FRIDAY, JULY 27

MORNING SESSION

7:30 AM – 1:15 PM | Banff Centre for Arts & Creativity | Room KC203

7:30 – 8:00 AM

REGISTRATION/BREAKFAST

Vistas Dining Room

PI Meeting (Closed Session)

Tanya Trippett, MD, Co-Founder and Director POETIC

Cynthia Herzog, MD, MD Anderson Cancer Center

Lisa McGregor, MD, Pennsylvania State Medical Center

Joseph DeStefano, Research Program Director, POETIC

8:00 – 8:40 AM

8:40 – 10:40 AM

POETIC Translational Genomics Program

Translational Genomics of Neuroblastoma: New Findings

David Lyden, MD, PhD, Weill Cornell Medical Center

Olga Kovalchuk, MD, PhD, University of Lethbridge

Bodour Salhia, PhD, University of Southern California

Michael Berger, PhD, Memorial Sloan Kettering Cancer Center*

Michael Roehrl, MD, PhD, Memorial Sloan Kettering Cancer Center*

8:40 – 9:40 AM

*Will be attending via conference call.

Translational Genomics of Osteosarcoma: New Findings

David Lyden, MD, PhD, Weill Cornell Medical Center

Olga Kovalchuk, MD, PhD, University of Lethbridge

Bodour Salhia, PhD, University of Southern California

Michael Berger, PhD, Memorial Sloan Kettering Cancer Center*

Michael Roehrl, MD, PhD, Memorial Sloan Kettering Cancer Center*

9:40 – 10:40 AM

*Will be attending via conference call.

10:40 – 10:45 AM

BREAK

10:45 – 11:15 AM

cBioPortal: Clinician Interface

Angelica Ochoa, PhD, Memorial Sloan Kettering Cancer Center

11:15 AM – 12:15 PM

PEDIATRIC CANCER MODELING

11:15 – 11:45 AM

Organoids

Michele Cioffi, PhD, Weill Cornell Medical Center

11:45 AM – 12:15 PM

Multi-Parallel Molecular and Immunologic Profiling in Relapsed/Refractory Pediatric Tumors – A Multicenter POETIC Biology Study

Tanya Trippett, MD, Memorial Sloan Kettering Cancer Center

Norman Lacayo, MD, Lucile Packard Children's Hospital

12:15 – 1:15 PM

LUNCH

Vistas Dining Room

AFTERNOON SESSION

1:15 – 4:15 PM | Banff Centre for Arts & Creativity | Room KC203

1:15 – 2:45 PM

ABSTRACT PRESENTATIONS

1:15 – 1:45 PM

Clinical Abstract Presentations

10 Minute Presentations each (3)

1:45 – 2:45 PM

Biology Abstract Presentations

10 Minute Presentations each (6)

2:45 – 2:50 PM

BREAK

2:50 – 3:20 PM

Tolero Pipeline: TP-0184 in DIPG

Steve Weitman, MD, PhD, University of Texas Health Sciences Center

3:20 – 3:40 PM

Larotrectinib for Pediatric Solid Tumors Harboring NTRK Gene Fusions

Josh Silvertown PhD, MBA, MSM, Medical Affairs Strategist – Oncology

Bayer Inc., Medical & Scientific Affairs, Pharmaceuticals

3:40 – 4:10 PM

ACTIVE CLINICAL TRIALS

3:40 – 3:55 PM

Phase I Study of Carfilzomib, Cyclophosphamide, Etoposide

PI: Jessica Boklan, MD, Phoenix Children's Hospital

3:55 – 4:10 PM

***Phase I/II Trial of Neratinib in Pediatric Malignancies
(Closed Session)***

PI: Tanya Trippett, MD, Memorial Sloan Kettering Cancer Center

4:10 – 4:15 PM

OUTTAKE

4:15 PM

ADJOURN

